{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T10:06:21Z","timestamp":1768644381907,"version":"3.49.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Despite better accessibility of the effective lipid-lowering therapies, only about 20% of patients at very high cardiovascular risk achieve the low-density lipoprotein cholesterol (LDL-C) goals. There is a large disparity between European countries with worse results observed for the Central and Eastern Europe (CEE) patients. One of the main reasons for this ineffectiveness is therapeutic inertia related to the limited access to appropriate therapy and suitable dosage intensity. Thus, we aimed to compare the differences in physicians\u2019 therapeutic decisions on alirocumab dose selection, and factors affecting these in CEE countries vs. other countries included in the ODYSSEY APPRISE study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>ODYSSEY APPRISE was a prospective, single-arm, phase 3b open-label (\u226512 weeks to \u226430 months) study with alirocumab. Patients received 75 or 150 mg of alirocumab every 2 weeks, with dose adjustment during the study based on physician's judgment. The CEE group in the study included Czechia, Greece, Hungary, Poland, Romania, Slovakia, and Slovenia, which we compared with the other nine European countries (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Spain, and Switzerland) plus Canada.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 921 patients on alirocumab were involved [modified intention-to-treat (mITT) analysis], including 114 (12.4%) subjects from CEE countries. Therapy in CEE vs. other countries was numerically more frequently started with lower alirocumab dose (75 mg) at the first visit (74.6 vs. 68%, <jats:italic>p<\/jats:italic>\u2009=\u20090.16). Since week 36, the higher dose was predominantly used in CEE patients (150 mg dose in 51.6% patients), which was maintained by the end of the study. Altogether, alirocumab dose was significantly more often increased by CEE physicians (54.1 vs. 39.9%, <jats:italic>p<\/jats:italic>\u2009=\u20090.013). Therefore, more patients achieved LDL-C goal at the end of the study (&amp;lt;55 mg\/dl\/1.4 mmol\/L and 50% reduction of LDL-C: 32.5% vs. 28.8%). The only factor significantly influencing the decision on dose of alirocumab was LDL-C level for both countries\u2019 groups (CEE: 199.2 vs. 175.3 mg\/dl; <jats:italic>p<\/jats:italic>\u2009=\u20090.019; other: 205.9 vs. 171.6 mg\/dl; <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001, for 150 and 75 mg of alirocumab, respectively) which was also confirmed in multivariable analysis (OR\u2009=\u20091.10; 95% CI: 1.07\u20131.13).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Despite larger unmet needs and regional disparities in LDL-C targets achievement in CEE countries, more physicians in this region tend to use the higher dose of alirocumab, they are more prone to increase the dose, which is associated with a higher proportion of patients reaching LDL-C goals. The only factor that significantly influences decision whether to increase or decrease the dose of alirocumab is LDL-C level.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2023.1206551","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T05:24:42Z","timestamp":1687152282000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Regional differences in physicians\u2019 behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study"],"prefix":"10.3389","volume":"10","author":[{"given":"Maciej","family":"Banach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Lewek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaja","family":"Pol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Rabczenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serban M.","family":"Balanescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Blaha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Ceska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Jankowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanis\u0142aw","family":"Surma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genovefa","family":"Kolovou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Liberopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florin","family":"Mitu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magda","family":"Mitu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franjo Husam","family":"Naji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyorgy","family":"Paragh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Pop\u0142awska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Vrablik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Pella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1161\/CIRCULATIONAHA.121.057889","article-title":"Temporal trends in the remaining lifetime risk of cardiovascular disease among middle-aged adults across 6 decades: the Framingham study","volume":"145","author":"Vasan","year":"2022","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3390\/ijms23010193","article-title":"Fibrinogen and atherosclerotic cardiovascular diseases-review of the literature and clinical studies","volume":"23","author":"Surma","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e9349","DOI":"10.7759\/cureus.9349","article-title":"Global epidemiology of ischemic heart disease: results from the global burden of disease study","volume":"12","author":"Khan","year":"2020","journal-title":"Cureus"},{"key":"B5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1474-4422(21)00252-0","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"20","year":"2021","journal-title":"Lancet Neurol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.5114\/aoms\/141941","article-title":"PoLA\/CFPiP\/PCS\/PSLD\/PSD\/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021","volume":"17","author":"Banach","year":"2021","journal-title":"Arch Med Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/nrcardio.2015.208","article-title":"Dyslipidaemia in 2015: advances in treatment of dyslipidaemia","volume":"13","author":"Grundy","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"DA VINCI study. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2021.08.035","article-title":"Lipid-lowering therapy use in primary and secondary care in central and Eastern Europe: DA VINCI observational study","volume":"334","author":"Vrablik","year":"2021","journal-title":"Atherosclerosis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1093\/eurjpc\/zwaa097","article-title":"Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study","volume":"28","author":"Gaudet","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.5114\/aoms\/143476","article-title":"Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE","volume":"18","author":"Banach","year":"2021","journal-title":"Arch Med Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"B15","doi-asserted-by":"publisher","first-page":"105499","DOI":"10.1016\/j.phrs.2021.105499","article-title":"Optimal use of lipid-lowering therapy after acute coronary syndromes: a position paper endorsed by the international lipid expert panel (ILEP)","volume":"166","author":"Banach","year":"2021","journal-title":"Pharmacol Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.5114\/aoms\/156147","article-title":"2022: the year in cardiovascular disease\u2014the year of upfront lipid lowering combination therapy","volume":"18","author":"Banach","year":"2022","journal-title":"Arch Med Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.phrs.2018.12.002","article-title":"Characteristics of lipid profile and effectiveness of management of dyslipidaemia in patients with acute coronary syndromes\u2014data from the TERCET registry with 19,287 patients","volume":"139","author":"Dyrbus","year":"2019","journal-title":"Pharmacol Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e0232845","DOI":"10.1371\/journal.pone.0232845","article-title":"30-year trends in major cardiovascular risk factors in the Czech population, Czech MONICA and Czech post-MONICA, 1985\u20132016\/17","volume":"15","author":"C\u00edfkov\u00e1","year":"2020","journal-title":"PLoS One"},{"key":"B20","doi-asserted-by":"publisher","first-page":"359","DOI":"10.33963\/KP.a2023.0045","article-title":"Dyslipidemia treatment and attainment of LDL-cholesterol treatment goals in patients participating in the managed care for acute myocardial infarction survivors program","author":"Nowowiejska-Wiewi\u00f3ra","year":"2023","journal-title":"Kardiol Pol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.atherosclerosis.2010.09.014","article-title":"Physicians\u2019 perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey","volume":"213","author":"Reiner","year":"2010","journal-title":"Atherosclerosis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"020702","DOI":"10.7189\/jogh.07.020702","article-title":"Effect of physician characteristics and knowledge on the quality of dyslipidemia management and LDL-C target goal achievement in China: subgroup analysis of the dyslipidemia international study","volume":"7","author":"Ding","year":"2017","journal-title":"J Glob Health"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1161\/CIRCULATIONAHA.113.003589","article-title":"Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarction","volume":"129","author":"Arnold","year":"2014","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12933-022-01684-5","article-title":"Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach (2022)","volume":"21","author":"Banach","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"00026","DOI":"10.1016\/j.pcad.2023.03.001","article-title":"Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)","author":"Banach","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.5114\/aoms\/152921","article-title":"Metabolic syndrome\u2014a new definition and management guidelines: a joint position paper by the Polish society of hypertension, Polish society for the treatment of obesity, Polish lipid association, Polish association for study of liver, Polish society of family medicine, Polish society of lifestyle medicine, division of prevention and epidemiology Polish cardiac society, \u201cclub 30\u201d Polish cardiac society, and division of metabolic and bariatric surgery society of Polish surgeons","volume":"18","author":"Dobrowolski","year":"2022","journal-title":"Arch Med Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"569","DOI":"10.5114\/aoms\/147435","article-title":"Which patients at risk of cardiovascular disease might benefit the most from inclisiran? Polish experts\u2019 opinion. The compromise between EBM and possibilities in healthcare","volume":"18","author":"Banach","year":"2022","journal-title":"Arch Med Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s11883-022-01008-8","article-title":"PCSK9 Inhibitors in real-world practice: analysis of data from 314 patients and 2 years of experience in a center of preventive cardiology","volume":"24","author":"Altschmiedov\u00e1","year":"2022","journal-title":"Curr Atheroscler Rep"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1206551\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T05:24:45Z","timestamp":1687152285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1206551\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,19]]},"references-count":28,"alternative-id":["10.3389\/fcvm.2023.1206551"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1206551","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,19]]},"article-number":"1206551"}}